For instance, CD19-targeted CAR-T cell therapies have achieved high complete remission rates in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) (4). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.